E I Pyott David Exercises Options at Alnylam Pharmaceuticals Inc (ALNY) — SEC Form 4, Nov 12, 2026

SEC Form 4 · No Market Transaction
Option Exercise

Derivative exercise — no open market transaction.

Reporting Owner
Director
TXN 2026-11-10 · FILED 2026-11-12
Equity Position 33.3K sh 29,482 → 33,262
Equity Change +12.8% shares held after vs before
Filing Lag 1 business day within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Filing Date
2026-11-12
Report Date
2026-11-12
Accession No.
0001178670-26-000089
Accepted At
2026-11-12 21:07 UTC
Reporting Owner
Name Relationship
E I Pyott David CIK 0001051578
Director
E I Pyott David at Alnylam Pharmaceuticals Inc Full insider history
Bought (12 mo) —
Sold (12 mo) $1,145,853
More from this insider at Alnylam Pharmaceuticals Inc
2026-06-03 Sell -$1,145,853 View
2026-05-22 Award — View
2025-05-12 Award — View
2025-03-25 Sell -$2,224,560 View
2024-06-26 Sell -$7,161,360 View
All filings by this insider at Alnylam Pharmaceuticals Inc
Non-Derivative Securities Transactions
Title Date Type Shares Price Net Total Post-Txn Ownership
Common StockF1 2026-11-10 M - Exercise 3,780 A $71.99 +$272,122 5,362 Direct
Derivative Securities Transactions
Title Strike Date Type Shares Price Expiration Underlying Ownership
Stock Option (Right to Buy)F1 $71.99 2026-11-10 M - Exercise 3,780 D $0.00 2027-06-01 3,780 Common Stock Direct
Non-Derivative Holdings
Title Shares Held Ownership
Common StockF2 27,900 Indirect by Trust
Footnotes (2)
F1
The options exercised and held by the reporting person were due to expire on June 1, 2027. Show more
F2
The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee. Show more
5%+ Holders · 13D/G 6 filers
Other insiders at Alnylam Pharmaceuticals Inc
All Alnylam Pharmaceuticals Inc insider activity
GET /v1/forms/4/0001178670-26-000089 API docs
View Original SEC Filing